Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Kuniaki Ohara
Comment on ‘Efficacy and Toxicity of Treatment With the Anti-Ctla-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-Pd-1 Therapy’
British Journal of Cancer
Cancer Research
Oncology
Angioma Serpiginosum
Archives of Dermatology
Related publications
Ipilimumab: An Anti-Ctla-4 Antibody for Metastatic Melanoma
Clinical Cancer Research
Cancer Research
Oncology
CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients
JCI insight
Medicine
Factors Influencing the Efficacy of Anti-Pd-1 Therapy in Chinese Patients With Advanced Melanoma
Journal of Oncology
Oncology
Site‐specific Response Patterns, Pseudoprogression, and Acquired Resistance in Patients With Melanoma Treated With Ipilimumab Combined With Anti–PD‐1 Therapy
Cancer
Cancer Research
Oncology
Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Associated With Partial Melanoma Response Under Anti-Ctla-4 and Anti-Pd-1 Combination
Arthritis and Rheumatology
Rheumatology
Allergy
Immunology
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-Ctla-4 Therapy in Metastatic Melanoma From the Ipilimumab Network
PLoS ONE
Multidisciplinary
Comprehensive Molecular and Clinical Characterization of Asian Melanoma Patients Treated With Anti-Pd-1 Antibody
BMC Cancer
Cancer Research
Oncology
Genetics
Corrigendum: Association of CTLA-4 Gene Variants With Response to Therapy and Long-Term Survival in Metastatic Melanoma Patients Treated With Ipilimumab: An Italian Melanoma Intergroup Study
Frontiers in Immunology
Allergy
Immunology
Improved Survival With T Cell Clonotype Stability After Anti-Ctla-4 Treatment in Cancer Patients
Science Translational Medicine
Medicine
